CX-4945
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme that plays a role in the development of cancerous cells through cellular processes such as cell cycle regulation, cellular signaling, blood vessel formation, inflammation, and cellular proliferation.
Clinical Trials:
Currently, there is one open clinical trial studying CX-4945 for multiple myeloma.
Source: Cylene Pharmaceuticals, http://www.cylenepharma.com/cylene/cx_4945 (as of November 14, 2009)
Leave a comment